Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Deutsches Herzzentrum Berlin
Ultrafiltration is effective for elimination of therapeutic levels of tirofiban
December 7th, 2004
An in vitro investigation reported on the extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass. According to recent research from Germany, "The short-acting platelet glycoprotein IIb/IIIa antagonist tirofiban is beneficial when used in the context of cardiac surgery. Tirofiban has an elimination half-life of 2 h. Renal failure prolongs the half-life and continues inhibition of platelet aggregation refractory to transfusions of platelets. Extracorporeal elimination is necessary to prevent excessive hemorrhage in this condition." A. Koster and colleagues of Deutsches Herzzentrum...
Source: Cardiovascular Business Week (2004-12-07)
|
